Bellvitge Biomedical Research Institute - IDIBELL’s Post

Researchers find that activation of a protein called the Liver X receptor (LXR) can promote regeneration and suppress tumor growth in colorectal cancer... #cancer #cancerresearch #lxr #colorectal #ibd #intestines

Microrobots made of algae carry chemo directly to lung tumors, improving cancer treatment: https://lnkd.in/eDwzmvV5

Researchers at Karolinska Institutet have found a molecule that can both help the intestines to heal after damage and suppress tumor growth in colorectal cancer. The discovery could lead to new treatments for inflammatory bowel disease (IBD) and cancer. The results are published in the journal Nature.

🔬 Research in the Spotlight 🔍 Researchers at MIT have developed innovative tiny gold nanoparticles designed for implantation at tumor sites. These particles deliver a dual therapy approach, combining heat and chemotherapy to target and treat the affected area effectively. This groundbreaking advancement holds promising potential in enhancing treatment outcomes for patients facing cancer. Link to manuscript: https://lnkd.in/eQfpbSpN #MITResearch #CancerTreatment #cancer #research #mit #nanoparticles #breastcancer #NIR #nearinfrared #photoactivated #cytotoxicity #machinelearning #ResearchInTheSpotlight #Innovation #Science #Technology

#PaperSpotlight: On May 20, 2024, researchers Gregory L. Guzik and Ankit Mangla from University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, and Case Comprehensive Cancer Center published a new editorial paper in Oncoscience, entitled, “Primary hepatic angiosarcoma: Treatment options for a rare tumor.” “[...] PHA is a rare yet aggressive mesenchymal tumor of the liver, which requires a multi-disciplinary approach to achieve the best patient outcomes.” #PressRelease: https://lnkd.in/eN2eUhCY #cancerresearch #angiosarcoma #liver #immunotherapy #oncology #openaccess #openscience #peerreviewed #journal #meded #publishing #publication #spotlight

The cytotoxic effects of chemotherapy are promiscuous and damaging to the entire body, which, ironically, weaken a patient’s natural defences against cancer. Our latest study demonstrates that non-invasive and targetable magnetic fields can enhance doxorubicin uptake into cancer cells without implicating healthy tissues. This novel therapeutic strategy may ultimately allow for the lowering of systemic doxorubicin load and improve a patient’s outcome against cancer. Our sincerest gratitude to NUS Centre for Cancer Research (N2CR) and iHealthtech, National University of Singapore for supporting these studies. #breastcancer #cancerresearch #magneticfieldtherapy #nusresearch #chemotherapy

📍 I am pleased to share our recently published systematic review titled " Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making". The lack of external validation of predictive models is a major issue that can potentially limit the reliability and applicability of predictive models in clinical settings. This paper highlights different externally validated methods of predicting response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) patients and how they could improve clinical decision-making. 📄 Thanks to Dr. Luca Boldrini and all other co-authors for their contribution. 😊 😊 😊 . Link: https://lnkd.in/et_Hy53Y

An MRI-based imaging technique developed by our emeritus Professor Kevin Brindle and colleagues at the Cancer Research UK Cambridge Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working. Read more: https://lnkd.in/enBe7Rsa

Study Suggests MRI Scans Could Replace Biopsies in Prostate Cancer Screening Could MRI scans replace biopsies in prostate cancer screening? A promising new study from Europe suggests that in some cases, men with elevated PSA levels may be able to skip traditional biopsies and rely on MRI scans instead. For many men, an abnormal prostate-specific antigen (PSA) test result is the first sign of possible prostate #Biopsies #MRI #ProstateCancer >>> Read more

Thoughtful Post for Future Cancer Health Care Our medonctherapeutics: https://lnkd.in/gaSXQicx website renewal is paused for business development progress. Advancement to Curtin University tissue therapy research Circulating tumour spheroids technology: Circulating tumour cell advantage over tissue tumour cell Minimal invasive clinical procedures.  Serial biopsies can be done with ease.  To know the current cancer status.  Whole-body cancer stem cells can be captured.  We can identify, correct and target the circulating cancer-initiating cell germline and somatic mutations.  Do not express ECM tissue-specific cell attachment surface markers. The powerful drug development tool. Do we have the technology to detect EMTs and MET CTCs? How many are peer-reviewed and patented, including our unpublished-developed feasibility study for commercial clinical application? What tests have reached the cancer clinics in Perth and India? Easy to use. Less complication, painful and invasive To evaluate and reproduce stem cell/cancer stem cell characteristics. Can predict the metastatic potential of the tumour. Drug efficacy testing outside the patient. Serum-free condition. Ability to capture multicellular tumour types. Specifically, it aims to identify and target the cancer-initiating cells and somatic and germ-line mutations. Do not express tissue-specific ECM cell attachment surface markers. Would you be interested in such products? Contact us at https://lnkd.in/gaSXQicx #circulatingtumourcell#circulatingcancerstemcell#circulatingtumourspheres Journal Club for Liquid Biopsy Knowledge Empowerment A 2022 Int J Mol Sci. 2022 Nov 24;23(23):14687 peer-reviewed pilot study on high-grade serous ovarian cancer using ISET and Cell Search System to detect CD45+/MC1-R+ or CD45+/EpCAM+ cells hybrid cancer and leukocyte CTCs. Read More Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade Ovarian Serous Carcinoma. Ruano APC, Gadelha Guimarães AP, Braun AC, Flores BCTCP, Tariki MS, Abdallah EA, Torres JA, Nunes DN, Tirapelli B, de Lima VCC, Fanelli MF, Colombo PE, da Costa AABA, Alix-Panabières C, Chinen LTD.Int J Mol Sci. 2022 Nov 24;23(23):14687